Spirocyclic compounds as innovative tools in drug discovery for medicinal chemists
- PMID: 39952099
- DOI: 10.1016/j.ejmech.2025.117368
Spirocyclic compounds as innovative tools in drug discovery for medicinal chemists
Abstract
The occurrence of spirocyclic motifs in clinical candidates and approved drugs is on the rise. This is related to the improvement of drug-like properties that can be achieved by introducing this sp3-rich system into bioactive compounds. Given the increasing number of synthetic methodologies and building blocks available, spirocycles are becoming widely accessible to medicinal chemists. From restricting conformation to induce a better fit with the target, to modulation of physicochemical and pharmacokinetic properties, spirocycles are being used to address several challenges in drug discovery. This review covers general aspects of the chemistry of spirocycles, highlighting some key strategies for their preparation. As reported in publications over the past five years, we demonstrate that, beyond the exploration of structure-activity relationships (SAR) in medicinal chemistry, the use of spirocycles is an attractive approach for enhancing properties such as potency, selectivity, physicochemistry, and pharmacokinetics.
Keywords: Lipophilicity; Metabolic stability; Multiparametric optimization; Spatial configuration; hERG inhibition.
Copyright © 2025 Elsevier Masson SAS. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Luiz Carlos Dias reports financial support was provided by State of Sao Paulo Research Foundation. Marina T. Varela reports financial support was provided by State of Sao Paulo Research Foundation. Gleiston G. Dias reports financial support was provided by State of Sao Paulo Research Foundation. Luiz Fernando N. de Oliveira reports financial support was provided by State of Sao Paulo Research Foundation. Ramon G. de Oliveira reports financial support was provided by State of Sao Paulo Research Foundation. Francielle D. Aguiar reports financial support was provided by Coordination of Higher Education Personnel Improvement. Joao Pedro Nogueira reports financial support was provided by State of Sao Paulo Research Foundation. Luiza R. Cruz reports financial support was provided by Drugs for Neglected Diseases initiative. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
